Commercially available 3D regimen, i.e. ombitasvir, paritaprevir and ritonavir tablets (Viekirax®, AbbVie Deutschland GmbH & Co. KG, Germany) and dasabuvir tablets (Exviera®, AbbVie Deutschland GmbH & Co. KG, Germany), was used as per routine clinical practice, local label and guidelines. The treatment regimen was at the discretion of the physician and was decided upon prior to offering the patient the opportunity to participate in the study.
Exviera
Manufactured by Abbvie
Sourced in Germany
Exviera is a piece of laboratory equipment used for research and testing purposes. It is designed to perform a core function, but a detailed description cannot be provided while maintaining an unbiased and factual approach.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using exviera
1
Commercially Available 3D Regimen for Hepatitis C
2
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Treatment for Chronic Hepatitis C
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The treatment consisted of two tablets of 12.5 mg ombitasvir, 75 mg paritaprevir, and 50 mg ritonavir (Viekirax ; AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany) once daily and one tablet of 250 mg dasabuvir (Exviera ; AbbVie Deutschland GmbH & Co. KG) twice daily for an 8-or 12-week period, according to the clinical judgement of the treating physician.
Per routine clinical practice, patients underwent pretreatment clinical assessments of hepatic fibrosis with transient elastography (TE; FibroScan , EchoSens, Paris, France) or FibroMax (BioPredictive, Paris, France). Transient elastography evaluation was performed in fasting conditions for ≥4 hours; a cut-off of 7 kPa for stage 1 of fibrosis and a cut-off of 9.5 kPa for stage 2 of fibrosis was used [12, (link)13] (link). For FibroMax assessments, the cut-offs were 0.31 for stage F1 and 0.58 for stage F2 [13, (link)14] (link). Serum HCV RNA was measured before starting the treatment and 12 weeks after the end of treatment (ie, ≥70 days) for all patients using a polymerase chain reaction test with a lower limit of quantification (LLoQ) of <15 IU/mL. Sustained virologic response 12 weeks after the end of treatment (SVR12) was defined as an HCV RNA level below the LLoQ [13] (link).
Per routine clinical practice, patients underwent pretreatment clinical assessments of hepatic fibrosis with transient elastography (TE; FibroScan , EchoSens, Paris, France) or FibroMax (BioPredictive, Paris, France). Transient elastography evaluation was performed in fasting conditions for ≥4 hours; a cut-off of 7 kPa for stage 1 of fibrosis and a cut-off of 9.5 kPa for stage 2 of fibrosis was used [12, (link)13] (link). For FibroMax assessments, the cut-offs were 0.31 for stage F1 and 0.58 for stage F2 [13, (link)14] (link). Serum HCV RNA was measured before starting the treatment and 12 weeks after the end of treatment (ie, ≥70 days) for all patients using a polymerase chain reaction test with a lower limit of quantification (LLoQ) of <15 IU/mL. Sustained virologic response 12 weeks after the end of treatment (SVR12) was defined as an HCV RNA level below the LLoQ [13] (link).
3
Hepatitis C Treatment Regimens Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients were treated with sofosbuvir (SOF) in combination with simeprevir (SMV), daclatasvir (DCV), or ledipasvir (LDV), or the 3D regimen. SOF (Sovaldi (Gilead, Cambridge, UK) 400 mg once daily), SMV (Olysio (Janssen, Beerse, Belgium) 150 mg once daily), DCV (Daklinza (Bristol-Myers Squibb, Uxbridge, UK) 60 mg once daily), SOF/LDV (Harvoni (Gilead, Cambridge, UK) 400 mg/ 90 mg once daily), and the 3D regimen (Viekirax (AbbVie, Maidenhead, UK) 12.5 mg ombitasvir, 75 mg paritaprevir, and 50 mg ritonavir once daily plus Exviera (AbbVie, Maidenhead, UK) 250 mg dasabuvir twice daily) were either prescription drugs or provided by pharmaceutical companies. Treatment durations ranged from 12 to 24 weeks.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!